Fix a second identity-merging bug: replace (MW,pI)-string protein grouping with an explicit real-molecule identity, and correct pI for 5 of 13 proteins (Trastuzumab, Omalizumab, Adalimumab, a TUR01/adalimumab-biosimilar row, a bispecific stated in its source paper). Previously up to 4 different real antibodies were silently pooled into one fake protein via colliding placeholder pI values.
fb0f432 verified | protein_id,protein_mw_kda,protein_pi,protein_tm_baseline_c,buffer_species,buffer_conc_mm,ph,ionic_strength_mm,osmolarity_mosm_kg,stabilizers_json,temperature_c,stability_score,measured_aggregation_percent,measured_tm_shift_c,source_title,source_id,protein_pi_original,pi_corrected,pi_correction_source,real_protein_id | |
| PGT121_acetate_baseline,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01}",50.0,0.5,50.0,-2.0,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243,7.0,False,,PGT121 | |
| PGT121_acetate_MoNi,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01, ""MoNi_copolymer"": 10.0}",50.0,0.7,30.0,1.5,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243,7.0,False,,PGT121 | |
| Adalimumab_commercial,148.0,8.5,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 50.0, ""polysorbate80"": 0.01}",25.0,0.95,5.0,0.0,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033,7.2,True,"icIEF main isoform, PMC5240642/PMC7272391",Adalimumab | |
| Adalimumab_concentrated_mannitol,148.0,8.5,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",4.0,0.98,2.0,0.5,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033,7.2,True,"icIEF main isoform, PMC5240642/PMC7272391",Adalimumab | |
| Adalimumab_concentrated_mannitol_RT,148.0,8.5,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",25.0,0.98,2.0,0.3,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033,7.2,True,"icIEF main isoform, PMC5240642/PMC7272391",Adalimumab | |
| X2Y1_bispecific_histidine,145.0,7.0,59.0,histidine,20.0,7.0,200.0,330.0,"{""sucrose"": 70.0, ""polysorbate80"": 0.01, ""arginine_hcl"": 200.0}",25.0,0.96,4.0,2.0,A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage,PMC11259756,7.0,False,,X2Y1_bispecific | |
| mAb2_citrate_baseline,150.0,7.2,65.0,citrate,25.0,6.0,165.0,300.0,{},25.0,0.85,15.0,-1.0,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517,7.2,False,,mAb2 | |
| mAb2_citrate_variant,150.0,7.2,66.5,citrate,25.0,6.0,165.0,300.0,{},25.0,0.92,8.0,1.5,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517,7.2,False,,mAb2 | |
| PGT121_acetate_baseline,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01}",50.0,0.5,50.0,-2.0,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243,7.0,False,,PGT121 | |
| PGT121_acetate_MoNi,146.0,7.0,60.0,acetate,20.0,5.2,50.0,150.0,"{""sucrose"": 90.0, ""polysorbate80"": 0.01, ""MoNi_copolymer"": 10.0}",50.0,0.7,30.0,1.5,Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient,PMC9854243,7.0,False,,PGT121 | |
| Adalimumab_commercial,148.0,8.5,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 50.0, ""polysorbate80"": 0.01}",25.0,0.95,5.0,0.0,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033,7.2,True,"icIEF main isoform, PMC5240642/PMC7272391",Adalimumab | |
| Adalimumab_concentrated_mannitol,148.0,8.5,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",4.0,0.98,2.0,0.5,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033,7.2,True,"icIEF main isoform, PMC5240642/PMC7272391",Adalimumab | |
| Adalimumab_concentrated_mannitol_RT,148.0,8.5,72.0,citrate,20.0,5.3,140.0,280.0,"{""mannitol"": 12.0, ""polysorbate80"": 0.01}",25.0,0.98,2.0,0.3,Stability of Monoclonal Antibodies as Solid Formulation for Auto-Injectors: A Pilot Study,PMC10459033,7.2,True,"icIEF main isoform, PMC5240642/PMC7272391",Adalimumab | |
| X2Y1_bispecific_histidine,145.0,7.0,59.0,histidine,20.0,7.0,200.0,330.0,"{""sucrose"": 70.0, ""polysorbate80"": 0.01, ""arginine_hcl"": 200.0}",25.0,0.96,4.0,2.0,A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage,PMC11259756,7.0,False,,X2Y1_bispecific | |
| mAb2_citrate_baseline,150.0,7.2,65.0,citrate,25.0,6.0,165.0,300.0,{},25.0,0.85,15.0,-1.0,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517,7.2,False,,mAb2 | |
| mAb2_citrate_variant,150.0,7.2,66.5,citrate,25.0,6.0,165.0,300.0,{},25.0,0.92,8.0,1.5,Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties,PMC7531517,7.2,False,,mAb2 | |
| Trastuzumab_histidine_reference,150.0,9.03,71.6,histidine,10.0,6.5,150.0,310.0,{},25.0,0.994,0.6,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152,7.2,True,PMC-indexed cIEF survey of 23 therapeutic mAbs,Trastuzumab | |
| Trastuzumab_arginine,150.0,9.03,68.6,histidine,10.0,6.5,150.0,310.0,"{""arginine_hcl"": 150.0}",25.0,1.0,0.0,-3.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152,7.2,True,PMC-indexed cIEF survey of 23 therapeutic mAbs,Trastuzumab | |
| Trastuzumab_glutamate,150.0,9.03,71.6,histidine,10.0,6.5,150.0,310.0,"{""sodium_glutamate"": 150.0}",25.0,0.994,0.6,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152,7.2,True,PMC-indexed cIEF survey of 23 therapeutic mAbs,Trastuzumab | |
| Omalizumab_histidine_reference,150.0,5.79,71.6,histidine,10.0,6.5,150.0,310.0,{},25.0,0.989,1.1,0.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152,7.2,True,"Fv sequence (Thera-SAbDab), Biopython ProtParam",Omalizumab | |
| Omalizumab_arginine,150.0,5.79,68.6,histidine,10.0,6.5,150.0,310.0,"{""arginine_hcl"": 150.0}",25.0,0.997,0.3,-3.0,Residue-resolved insights into the stabilization of therapeutic proteins by excipients,PMC11572152,7.2,True,"Fv sequence (Thera-SAbDab), Biopython ProtParam",Omalizumab | |
| bispecific_A_histidine_no_salt,110.0,8.52,58.0,histidine,50.0,5.5,0.0,150.0,{},25.0,0.96,4.0,-2.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937,6.9,True,"stated directly, PMC11343937",bispecific_A | |
| bispecific_A_histidine_150mM_NaCl,110.0,8.52,58.0,histidine,50.0,5.5,150.0,300.0,"{""nacl"": 150.0}",25.0,0.94,6.0,-1.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937,6.9,True,"stated directly, PMC11343937",bispecific_A | |
| bispecific_A_histidine_500mM_NaCl,110.0,8.52,58.0,histidine,50.0,5.5,500.0,900.0,"{""nacl"": 500.0}",25.0,0.937,6.3,-1.2,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937,6.9,True,"stated directly, PMC11343937",bispecific_A | |
| bispecific_A_histidine_Arg,110.0,8.52,58.0,histidine,50.0,5.5,150.0,300.0,"{""arginine_hcl"": 150.0}",25.0,0.941,5.9,-1.0,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937,6.9,True,"stated directly, PMC11343937",bispecific_A | |
| bispecific_A_acetate,110.0,8.52,58.0,acetate,50.0,5.5,50.0,180.0,{},25.0,0.944,5.6,-1.5,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937,6.9,True,"stated directly, PMC11343937",bispecific_A | |
| bispecific_A_citrate,110.0,8.52,58.0,citrate,50.0,5.5,50.0,180.0,{},25.0,0.961,3.9,-1.8,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937,6.9,True,"stated directly, PMC11343937",bispecific_A | |
| bispecific_A_phosphate,110.0,8.52,58.0,phosphate,50.0,5.5,50.0,180.0,{},25.0,0.948,5.2,-1.4,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937,6.9,True,"stated directly, PMC11343937",bispecific_A | |
| bispecific_A_histidine_40C,110.0,8.52,58.0,histidine,50.0,5.5,0.0,150.0,{},40.0,0.95,5.0,-1.5,Investigation on environmental factors contributing to bispecific antibody stability,PMC11343937,6.9,True,"stated directly, PMC11343937",bispecific_A | |
| mAb_aggregation_prone_1,150.0,7.1,60.0,histidine,20.0,6.0,140.0,280.0,{},45.0,0.85,15.0,-0.5,Machine learning prediction of antibody aggregation and viscosity,PMC8794240,7.1,False,,mAb_devpanel_aggregation_prone | |
| mAb_stable_reference,150.0,7.1,55.0,histidine,20.0,6.0,140.0,280.0,{},45.0,0.97,3.0,1.0,Machine learning prediction of antibody aggregation and viscosity,PMC8794240,7.1,False,,mAb_devpanel_stable_reference | |
| mAb_high_viscosity_1,150.0,7.2,56.5,histidine,20.0,6.0,140.0,280.0,{},25.0,0.92,8.0,0.5,Machine learning prediction of antibody aggregation and viscosity,PMC8794240,7.2,False,,mAb_devpanel_high_viscosity | |
| A33_Fab_citrate_no_glycine,27.0,6.8,77.1,citrate,20.0,4.5,50.0,150.0,{},25.0,0.9,10.0,0.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065,6.8,False,,A33_Fab | |
| A33_Fab_citrate_glycine10,27.0,6.8,79.1,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 10.0}",25.0,0.92,8.0,2.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065,6.8,False,,A33_Fab | |
| A33_Fab_citrate_glycine20,27.0,6.8,79.6,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 20.0}",25.0,0.93,7.0,2.5,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065,6.8,False,,A33_Fab | |
| A33_Fab_citrate_glycine30,27.0,6.8,82.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 30.0}",25.0,0.94,6.0,5.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065,6.8,False,,A33_Fab | |
| A33_Fab_citrate_glycine40,27.0,6.8,82.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 40.0}",25.0,0.95,5.0,5.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065,6.8,False,,A33_Fab | |
| A33_Fab_citrate_glycine50,27.0,6.8,83.2,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 50.0}",25.0,0.96,4.0,6.1,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065,6.8,False,,A33_Fab | |
| A33_Fab_citrate_glycine60,27.0,6.8,83.6,citrate,20.0,4.5,50.0,150.0,"{""glycine"": 60.0}",25.0,0.97,3.0,6.5,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065,6.8,False,,A33_Fab | |
| A33_Fab_phosphate_glycine20,27.0,6.8,78.0,phosphate,10.0,7.0,50.0,150.0,"{""glycine"": 20.0}",25.0,0.94,6.0,1.0,Molecular Dynamics Simulations Reveal Protein-Surface Interactions Modulate Stability in Fab Formulations,PMC11539065,6.8,False,,A33_Fab | |
| Fab_citrate_dilute,27.5,6.9,70.8,citrate,20.0,4.0,200.0,400.0,{},25.0,0.88,12.0,0.0,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210,6.9,False,,Fab_PMC10155210 | |
| Fab_citrate_medium,27.5,6.9,77.2,citrate,20.0,4.0,200.0,400.0,{},25.0,0.93,7.0,6.4,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210,6.9,False,,Fab_PMC10155210 | |
| Fab_citrate_concentrated,27.5,6.9,79.9,citrate,20.0,4.0,200.0,400.0,{},25.0,0.95,5.0,9.1,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210,6.9,False,,Fab_PMC10155210 | |
| Fab_citrate_high_conc_tween80,27.5,6.9,79.9,citrate,20.0,4.0,200.0,400.0,"{""tween80"": 0.01}",25.0,0.96,4.0,9.1,Enhanced Thermal Stability and Reduced Aggregation in Fab Fragment at Elevated Concentrations,PMC10155210,6.9,False,,Fab_PMC10155210 | |
| Biosimilar_mAb_phosphate_cold,150.0,8.5,72.0,phosphate,20.0,7.4,188.0,380.0,{},5.0,0.98,2.0,0.0,Stability Evaluation of the Biosimilar Monoclonal Antibody Using Analytical Techniques,PMC9986942,7.3,True,TUR01 = adalimumab biosimilar (identical sequence),Biosimilar_mAb_TUR01 | |
| Biosimilar_mAb_phosphate_RT,150.0,8.5,72.0,phosphate,20.0,7.4,188.0,380.0,{},25.0,0.96,4.0,-2.0,Stability Evaluation of the Biosimilar Monoclonal Antibody Using Analytical Techniques,PMC9986942,7.3,True,TUR01 = adalimumab biosimilar (identical sequence),Biosimilar_mAb_TUR01 | |
| rhIL1ra_MES_60mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,60.0,140.0,"{""NaCl"": 60.0}",25.0,0.85,15.0,0.0,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359,5.6,False,,rhIL1ra | |
| rhIL1ra_MES_150mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,150.0,300.0,"{""NaCl"": 150.0}",25.0,0.9,10.0,1.0,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359,5.6,False,,rhIL1ra | |
| rhIL1ra_MES_500mM_NaCl,17.3,5.6,55.0,MES,10.0,6.5,500.0,950.0,"{""NaCl"": 500.0}",25.0,0.94,6.0,2.5,Protein-protein interactions controlling interfacial aggregation of rhIL-1ra,PMC6032359,5.6,False,,rhIL1ra | |